$AMRN - On out trading list. Company issued guidance for revenue and Vascepa sales as well as cash balance update.Amarin sees FY20 revenue $650M-$700M, consensus $687.48MAmarin anticipates most total net revenue in FY20 will come from sales of VASCEPA in the U.S. The guidance remains unchanged from the total net revenue guidance issued by the company on December 13, 2019. Beyond 2020, Amarin reiterates that it believes that VASCEPA total net revenue will grow to reach multiple billions of dollars. Because the rate of VASCEPA revenue growth is difficult to predict, in 2020 Amarin intends to spend approximately $250M on inventory purchases, which is approximately twice the amount spent for inventory purchases in 2019. Such planned purchases do not change Amarin's revenue guidance. Currently, Amarin anticipates operating expenses in 2020 to increase approximately $200M-$250M over 2019 levels. Amarin, after being cash flow positive in the Q2 and Q3, had net cash outflow of approximately $28M in the Q4 reflecting the expansion of the company's sales force and other costs associated with the new FDA-approved label for VASCEPA and the U.S. launch of this new label. Amarin anticipates starting 2020 with net cash outflows as it completes its sales force expansion and as these sales representatives become productive and other forms of expanded promotion take hold. On a steady-state basis, including the expanded sales force size, but excluding incremental purchases to build inventory and incremental spending for launch-level DTC, Amarin estimates that it needs approximately $150M in quarterly net revenue to collect adequate cash to achieve cashflow breakeven. Amarin estimates that approximately $200M in quarterly net revenue is required to generate required cash collections to achieve cashflow breakeven. Above these breakeven levels, additional cash inflows should be net positive. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page